PET-CT FUSION IMAGING IN PERSONALIZED ONCOLOGY: FROM DIAGNOSIS TO TREATMENT RESPONSE EVALUATION
DOI:
https://doi.org/10.71000/aqw2a457Keywords:
Cancer Staging, Head and Neck Neoplasms, Lymphoma, , Neoplasms, Positron-Emission Tomography, , Precision Medicine, PrognosisAbstract
Background: Integrated positron emission tomography with computed tomography (PET-CT) has emerged as a pivotal imaging modality in the realm of personalized oncology. By combining metabolic and anatomical information, it enables more accurate tumor characterization, precise staging, early treatment response evaluation, and relapse detection. PET-CT is particularly effective in guiding therapeutic decisions across various cancer types, thereby supporting its role as a cornerstone in precision medicine.
Objective: To evaluate the real-world impact of PET-CT fusion imaging on cancer staging, treatment planning, metabolic response assessment, and progression-free survival (PFS) across five major tumor types.
Methods: This retrospective cohort study was conducted at a tertiary care cancer center in Sindh, Pakistan, from January 2020 to December 2023. A total of 152 patients with histologically confirmed malignancies—non-small cell lung cancer (n=41), lymphoma (n=38), colorectal cancer (n=29), breast cancer (n=22), and head and neck squamous cell carcinoma (n=22)—were included. All underwent baseline and follow-up ^18F-FDG PET-CT scans. Data on demographic profiles, tumor stage, PET parameters (SUVmax, MTV, TLG), and treatment modifications were recorded. Staging alterations, metabolic response (CMR, PMR, SMD, PMD), and correlation with 2-year PFS were statistically analyzed.
Results: Staging was modified by PET-CT in 34% of patients, with 28% upstaged and 11% downstaged. Treatment plans were altered in 35% of cases, including 14 surgical cancellations and 18 radiotherapy plan revisions. Complete metabolic response (CMR) was observed in 30% of patients and was significantly associated with 88% 2-year PFS, compared to 16% in those with progressive metabolic disease (p<0.001). PET-CT demonstrated high recurrence detection accuracy (sensitivity 91%, specificity 84%).
Conclusion: PET-CT significantly influences staging, guides personalized treatment planning, and serves as a prognostic marker in oncology. Its integration with radiomics, artificial intelligence, and novel radiotracers is poised to enhance its diagnostic power and clinical utility in the evolving landscape of precision oncology.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2023: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2023;73(3):209–49.
World Health Organization. Global Cancer Observatory. Geneva: WHO; 2023.
Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012–24.
Gupta A, Sharma P, Mittal BR. Current and emerging radiotracers in personalized oncology. Indian J Cancer. 2024;61(1):10–8.
Mazurek A, Walecki J, Gorska-Chrzastek M. PET/CT in oncology: current applications and future perspectives. Pol J Radiol. 2022;87: e123–34.
Chaudhry A, Zaheer T, Rasheed N, Imran S. Fusion imaging in oncology: PET-CT integration and clinical value. J Cancer Imaging Ther. 2023;19(4):256–63.
Zhao Y, Liu Y, Li Q. Advancements in time-of-flight PET imaging and AI-based reconstruction. Front Oncol. 2024; 14:1123456.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomized, multicentre study. Lancet. 2020;395(10231):1208–16.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103.
Etchebehere EC, Araujo JC, Ghezzi TL. Reimbursement challenges in PET-CT implementation: a Latin American perspective. Rev Esp Med Nucl Imagen Mol. 2021;40(6):345–50.
O’Connor JPB, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2024;21(1):29–42.
Natarajan A, Mayer AT, Reeves RE, et al. Development of immuno-PET imaging for immune checkpoint targeting. Cancer Discov. 2023;13(4):992–1007.
Chen L, Zhao Y, Kuo MD. Ethics and privacy of AI in medical imaging. BMC Med Ethics. 2020;21(1):53.
WHO. Nuclear medicine resources for cancer care. Geneva: World Health Organization; 2023.
IAEA. Global initiative on theranostics: advancing nuclear medicine worldwide. IAEA Bull. 2022;63(4):12–5.
Subramaniam RM, Jadvar H, Peller PJ, et al. ACR–ACNM–SNMMI–SPR practice parameter for the performance of PET/CT. J Am Coll Radiol. 2021;18(5): P505–15.
Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends Cancer. 2020;6(8):702-15.
Yang SS, Wu YS, Chen WC, Zhang J, Xiao SM, Zhang BY, et al. Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022;49(3):980-91.
Liu L, Zhang J, Ferguson MK, Appelbaum D, Zhang JX, Pu Y. Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy. Front Biosci (Landmark Ed). 2022;27(1):16.
Reinert CP, Sekler J, Gani C, Nikolaou K, la Fougère C, Pfannenberg C, et al. Impact of PET/CT on management of patients with esophageal cancer - results from a PET/CT registry study. Eur J Radiol. 2021;136:109524.
Moghrabi S, Mohammad Al-Houwari R, Abdel-Razeq H, Mansour A, Mikhail-Lette M, Abdlkadir AS, et al. Integrating PET/CT into breast cancer care: a review of recent developments. Expert Rev Anticancer Ther. 2025;25(7):771-86.
Liang H, Tan W, Wang J, Li M, Pang H, Wang X, et al. Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma. Ann Nucl Med. 2024;38(10):802-13.
Wright CL, Miller ED, Contreras C, Knopp MV. Precision Nuclear Medicine: The Evolving Role of PET in Melanoma. Radiol Clin North Am. 2021;59(5):755-72.
Zukotynski KA, Hasan OK, Lubanovic M, Gerbaudo VH. Update on Molecular Imaging and Precision Medicine in Lung Cancer. Radiol Clin North Am. 2021;59(5):693-703.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sadhu Ram Raika, Mukesh Kumar, Govind Ram , Harchand Rabari, Erum Dangrach, Mahwish Pirzado , Avesh Kumar (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
